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Background: Feline immunodeficiency virus (FIV) infection is mediated by sequential interactions with CD134 and
CXCR4. Field strains of virus vary in their dependence on cysteine-rich domain 2 (CRD2) of CD134 for infection.
Findings: Here, we analyse the receptor usage of viral variants in the blood of 39 naturally infected cats, revealing
that CRD2-dependent viral variants dominate in early infection, evolving towards CRD2-independence with disease
progression.
Conclusions: These findings are consistent with a shift in CRD2 of CD134 usage with disease progression.
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The interaction between a virus and its cellular receptor
is a primary event in viral replication and the specificity
of the virus-receptor interaction influences both viral
cell tropism and pathogenicity. While the primate lenti-
viruses target helper T cells by binding to CD4 [1-3], the
feline immunodeficiency virus (FIV) attaches to helper T
cells through an interaction with CD134 (OX40) [4,5].
Infection with either the primate or the feline lentivi-
ruses requires a subsequent interaction with a member
of the seven transmembrane domain (7TM) superfamily
molecules; for the human immunodeficiency virus (HIV)
the major co-receptors are CXCR4 and CCR5 [6-10], while
FIV uses CXCR4 as a sole co-receptor [11,12].
Assessment of HIV-1 cell tropism may be used to moni-
tor disease progression [13,14] because progression is often
associated with the emergence of either X4 viruses or
dual-tropic viruses capable of using both CXCR4 and
CCR5, ( ? X4R5 ? viruses) [15]. The emergence of X4 var-
iants is usually accompanied by a rapid decline in the* Correspondence: margaret.hosie@glasgow.ac.uk
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article, unless otherwise stated.number of CD4+ Tcells and the onset of immunodeficiency
[16] and X4 or X4R5 viruses are present in 40-50% of
HIV-1-infected individuals who progress to AIDS [17-20].
Like HIV, the cell tropism of FIV alters with disease pro-
gression; while CD4+ T cells are the predominant target in
the acute (early) phase of infection, in the chronic (late)
phase of infection, FIV also targets CD8+ T cells and B
cells [21,22]. This shift in cell tropism between early and
late viruses would seem counter-intuitive given that FIV
infection is entirely dependent on sequential interac-
tions between Env and CD134 [4,5,23] and CXCR4
[11,12,23-26]. Resolution of this enigma is offered by
the observation that distinct strains of FIV differ in the
nature of their interactions with CD134 [27-30]. It has
been proposed that viruses requiring only CRD1 of CD134
for attachment (CRD2-independent strains) emerge during
the later stages of disease [30,31]. In contrast, viruses that
dominate in early infection require both CRD1 and CRD2
of CD134 for attachment (CRD2-dependent) [30,31]. The
selective pressure for the emergence of CRD2-independent
viruses may be escape from humoral or cellular immun-
ity, with the accrued mutations in Env impacting on the
virus-receptor interaction [30,32]. Consistent with thistral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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viral quasispecies containing equal titres of clonal variants
with either CRD2-dependent or CRD2-independent Envs
(early and late phenotypes), the CRD2-dependent viruses ex-
panded preferentially in vivo while the CRD2-independent
viruses failed to thrive [33].
Methods
In this study, we examined the phenotype of viral variants
isolated from outbred, privately owned US cats with
naturally acquired FIV infection [34]. Forty-four cats
were enrolled in the study on the basis of a history of
FIV infection (confirmed by virus isolation), regardless
of breed, sex, age and health status. Four blood sam-
ples (denoted A, B, C and D) were collected from each
cat at 6-monthly intervals over an 18-month period,
unless cats died during the interim period. The data re-
corded every 6 months included signalment, clinical
history, physical examination data and body weight, as
well as flow cytometric analyses of CD4+ and CD8+ T
cells [34].
Full-length FIV env genes were amplified from whole
blood using a two-step nested PCR protocol followed by
direct nucleic acid sequence determination [34]. The
nucleic acid sequence of the first-round PCR product
informed primer design for the second round PCR; strain-
specific primers [see Additional file 1: Table S1] for second
round PCR incorporated restriction sites to facilitate sub-
cloning into the expression vector for pseudotyping onto
HIV. HIV(FIV)luc pseudotypes were prepared as described
previously [4] by co-transfection of each Env construct withFigure 1 Representative example of results obtained from receptor u
cat M31 and two reference Envs, GL8 (CRD2-dependent) and B2542 (
each cell line with standard errors (n = 3) are presented for MCC cells [35] e
expressing the human x feline CD134 containing the human CRD2 domain
molecule (FFF and CLL-CD134 cells [29], shown in chequered and grey bar
human x feline CD134 chimaera containing the human CRD2 domain (FFH
CRD2-dependent or ? independent.pNL4-3-Luc-E−R−luc into HEK-293 T cells. Pseudotype-
containing culture fluids were harvested 72 hours post-
transfection and stored frozen at −80?C until required.
The CRD2-dependence of each pseudotype was deter-
mined using assays for receptor usage of FIV Envs using
MCC cells [35] expressing human (HHH), feline (FFF),
and a feline x human chimaeric CD134 molecule contain-
ing human CRD2 (FFHH), as described previously [27,29].
Sequential plasma samples from infected cats were di-
luted ten-fold from 1 in 10 to 1 in 10,000 in complete
RPMI 1640 medium (Life Technologies), before testing
for the presence of homologous and heterologous neutra-
lising antibodies (NAb) using HIV(FIV)luc pseudotypes as
described previously [36].
Results
FIV Envs displayed a broad spectrum of cell tropism in
naturally infected cats
While we cannot exclude the possibility that other vari-
ants existed in the cats, the methodology used provided
a snapshot of the spectrum of Env variants present at
each time point. The HIV(FIV) pseudotypes bearing FIV
Envs derived from 39 (39/44, 88.6%) of the infected cats
displayed a broad spectrum of cell tropisms (viable pseu-
dotypes bearing Envs from 5 cats were not produced,
predominantly because premature stop codons occurred
in the env sequences obtained from these cats). Of the
287 Envs tested, 222 (77.4%) were CRD2-dependent, uti-
lising CD134 in the same manner as the prototypic
? early ? isolate, GL-8 [Figure 1 and Table 1]. In contrast,
49 (17.0%) Envs were CRD2-independent, similar to thetilisation assay testing six autologous Env variants isolated from
CRD2-independent). The mean luciferase counts per minute (cpm) for
xpressing the entire human CD134 molecule (HHH, open bars), cells
(FFHH, hatched bars) and cells expressing the entire feline CD134
s respectively). Note the differences in titres on cells expressing the
H cells, hatched bars) and subsequent pseudotype classification as








M28 A H > 350 11 (100%) 0 0 11 -
M47 A H < 350 8 (100%) 0 0 8 +
M8 A S < 350 2 (100%) 0 0 2 -
P9 A S < 350 6 (100%) 0 0 6 +
M1 A H < 350 4 (100%) 0 0 4 -
M2 A H > 350 2 (100%) 0 0 2 +
M29 A H > 350 3 (100%) 0 0 3 -
P1 A H > 350 3 (100%) 0 0 3 -
P11 A H > 350 7 (100%) 0 0 7 +
P14 A H > 350 9 (100%) 0 0 9 +
P18 A H > 350 1 (100%) 0 0 1 +
P21 A H > 350 6 (100%) 0 0 6 -
P22 A H > 350 2 (100%) 0 0 2 +
P4 A H < 350 4 (44.4%) 2 (22.2%) 3 (33.3%) 9 +
P5 A H < 350 7 (87.5%) 1 (12.5%) 0 8 +
P6 A H > 350 8 (100%) 0 0 8 -
M15 A S > 350 6 (66.6%) 3 (33.3%) 0 9 +
M20 A S > 350 1 (100%) 0 0 1 -
M32 A S < 350 3 (75%) 1 (25%) 0 4 -
P13 A S < 350 8 (88.9%) 1 (11.1%) 0 9 +
P17 A S < 350 9 (100%) 0 0 9 -
P7 A S > 350 1 (50%) 0 1 (50%) 2 +
P8 A S > 350 5 (100%) 0 0 5 -
M25 D H < 350 3 (50%) 2 (33.3%) 1 (16.7%) 6 +
M46 D H < 350 7 (87.5%) 1 (12.5%) 0 8 +
M49 D H < 350 6 (100%) 0 0 6 +
M14 D S < 350 9 (90%) 1 (10%) 0 10 +
M26 D S < 350 4 (66.7%) 2 (33.3%) 0 6 +
M30 D S < 350 15 (94%) 1 (6%) 0 16 +
M33 D S < 350 2 (11%) 17 (89%) 0 19 -
M41 D S < 350 9 (75%) 2 (17%) 1 (8%) 12 -
M5 D S < 350 5 (55.6%) 3 (33.3%) 1 (11.1%) 9 -
M11 D H > 350 17 (81%) 3 (14%) 1 (5%) 21 -
M50 D H > 350 2 (100%) 0 0 2 -
P2 D H > 350 16 (100%) 0 0 16 +
M16 D S > 350 0 1 (14.3%) 6 (85.7%) 7 -
M3 D S < 350 0 1 (50%) 1 (50%) 2 -
M31 D S < 350 9 (53%) 7 (41%) 1 (6%) 17 +
M44 D S > 350 2 (100%) 0 0 2 +
Cats were classified according to their clinical status at the time of enrolment (H = clinically healthy, S = sick), CD4+ cell counts (< or >350 cells/μl) and survival
during the study period (A = alive, D = deceased). For absolute CD4+ T cell counts see Additional file 2 [Table S2]. Mode of CD134 interaction: numbers (and percentages)
of Envs classified as: 1) CRD2-dependent; 2) CRD2-independent; 3) intermediate requirement for determinants within CRD2. For homologous neutralisation, ? +? and ? -?
indicate≥ or <2.5 fold neutralisation, respectively. For complete neutralisation data see Additional file 3 [Table S3].
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Envs (5.6%) displayed an intermediate pattern of recep-
tor usage. Some cats (for example P4, M5 and M31) har-
boured a mixture of CRD2-dependent and -independent
Env variants.
CRD2-independence segregates with clinical status
Since CRD2-independent variants of FIV were present
in only a subset of the cats studied, we examined the
data for evidence of an association between clinical sta-
tus and the presence of CRD2-independent variants.
Since the duration of infection was unknown, cats were
grouped retrospectively according to their status at time
of last sampling: Alive or Dead; Clinically Healthy (no
clinical abnormalities detected on physical examination)
or Sick (at least one clinical abnormality detected); a
CD4 count >350 cells/μl or <350 cells/μl. Statistical ana-
lysis of viral load data revealed no significant differences
between cats that were classified as clinically healthy or
sick at the time of enrolment (data not shown). When
the number of cats giving rise to CRD2-independent
Env variants was compared between groups, a strong
association was noted between the presence of CRD2-
independent variants and a decline in clinical status
[Figure 2]. Samples collected from cats that died during
the study had a significantly higher proportion of CRD2-
independent variants than samples from cats that were
alive at the time of last sampling (p = 0.0038, Fisher ? s exact
test). Similarly, sick cats (displaying clinical signs) har-
boured more CRD2-independent viruses than healthy cats
(p = 0.0104, Fisher ? s exact test).
Given that a clinical assessment of health status may
be subjective, we next used a CD4 count <350 cells/μl as
indicative of CD4+ T cell depletion and progression toFigure 2 CRD2-independent Env variants were isolated more frequen
progression. Cats were classified into 3 groups: 1) alive/deceased, 2) clinic
died during the study, displayed clinical signs (sick) or had CD4+ T cell counts <
variant (chequered bars). Conversely, CRD2-dependent variants were associated
(grey bars). P-values (Fisher? s exact test) were shown below the x-axis.immunodeficiency (by analogy to WHO recommendations
for the initiation of antiretroviral therapy for HIV infection
[http://www.who.int/hiv/pub/guidelines/arv2013/en/]), for
data see Additional file 2: Table S2. We observed that im-
munodeficient cats were more likely to harbour CRD2-
independent Envs than cats with CD4 counts >350 cells/μl
(p = 0.0036, Fisher ? s exact test). Thus the presence of
CRD2-independent viruses was associated with declin-
ing clinical status.
Absence of correlation between CRD2-usage and
neutralising antibody response
When neutralisation profiles [see Additional file 3: Table S3]
were compared [Table 1], plasma from 10/17 cats har-
bouring at least one CRD2-independent Env variant neu-
tralised pseudotypes bearing homologous Envs, while the
remaining 7 cats showed no evidence of homologous neu-
tralisation (p = 0.75, Fisher? s exact test). Thus, no correl-
ation was observed between the presence of neutralising
antibodies and CRD2-independence, indicating that key
factors driving Env evolution remain to be discovered.
Loss of predicted N-linked glycosylation site was
associated with decrease in CRD2 dependence
A complete spectrum of receptor utilisation was observed
by pseudotypes bearing 21 Env variants isolated from
three time points from cat M11 (until its death); 17/21
were CRD2-dependent, 3/21 were CRD2-independent,
and one displayed an intermediate phenotype [Table 1].
Strikingly, the remaining pseudotype (M11A C242) in-
fected cells expressing the CD134 chimaera containing
the human CRD2 domain as efficiently as cells expressing
the entire feline CD134 molecule [see Additional file 4:
Figure S1]. Analysis of amino acid sequence alignmentstly from cats displaying signs of immunodeficiency and disease
ally healthy/sick, 3) CD4+ T cell counts > or <350 cells/μl. Cats which
350 cells/μl were more likely to harbour at least one CRD2-independent
with the alive, clinically healthy cats with CD4+ T cell counts >350 cells/μl
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which were present in M11A C242 Env but not any other
Env variants from this cat. The T520A substitution led to
the loss of a predicted site for N-linked glycosylation
(PNGS), consistent with a role for the T520A mutation in
the observed decrease in CRD2 dependence. To confirm
this observation, PCR-based site directed mutagenesis was
employed to exchange 1) alanine at residue 520 to threo-
nine (A520T) and 2) lysine at residue 838 to glutamate
(K838E), creating two mutants, namely M11A C242 T520
and M11A C242 E838 respectively. By comparing the re-
ceptor utilisation of these mutant Envs with the wild type
M11A C242 Env, we observed that the M11A C242 T520
mutant achieved a 10 fold lower titre on cells expressing
the human x feline CD134 chimaera containing the hu-
man CRD2 domain compared to either the parental wild
type M11A C242 or the M11A C242 E838 mutant Env,
consistent with residue A520 in the wild type Env (ablating
the PNGS) having an important role in receptor utilisation
[see Additional file 4: Figure S1].
To confirm the role of A520 and the subsequent loss
of a PNGS in determining receptor utilisation, mutants
of the Env clone M11C C164, (CRD2-dependent pheno-
type) were constructed. Substitution of T520 with A520 re-
sulted in the generation of mutant M11C C164 A520 that
productively infected cells expressing the human x feline
CD134 chimaera containing the human CRD2 domain
[see Additional file 4: Figure S1], consistent with a role for
the PNGS at residue 520 in modulating CRD2-dependence
and altering the virus-receptor interaction.
The envelope glycoprotein adopts a trimeric structure
upon the virion and it is likely that multiple determinants
within Env may affect the tertiary or quaternary structure
of the trimer, resulting in altered CD134 utilisation. The
data presented here are consistent with previous studies
[29,32] indicating that single mutations within the V1/V2
or V5 regions of Env alone, likely as a result of pressure
from the host immune response, may alter the structure
of Env sufficiently to drive the emergence of CD134
CRD2-independent variants of FIV. Whether the emer-
gence of such variants is a cause or consequence of dis-
ease progression remains to be established.
Conclusion
The studies described herein are consistent with the
dominance of CRD2-dependent viruses in early infection
and indicate that the emergence of CRD2-independent
viruses coincides with clinical decline towards immuno-
deficiency. Accordingly, viral phenotyping using HIV(FIV)
pseudotypes may assist with the clinical staging of FIV in-
fection. Moreover, if CRD2-dependent viruses dominate
in early infection, testing prototypic FIV vaccines against
challenge with CRD2-dependent strains of virus will likely
predict vaccine efficacy in the field.Additional files
Additional file 1: Table S1. Strain specific primer sequences.
Additional file 2: Table S2. CD4+ T cell counts (cells/μl) for each time
point.
Additional file 3: Table S3. Mode of CD134 utilisation for each Env
pseudotype.
Additional file 4: Figure S1. PNGS at the stem of V5 region of Env is
associated with distinct mode of receptor utilisation.
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